Naivek announced on the 12th that it discussed partnerships with over 30 global pharmaceutical companies at the ‘2024 BIO International Convention (BIO USA).’
Naivek introduced its overall business and engaged in various discussions with global pharmaceutical companies at BIO USA, held in the United States until the 6th. The company showcased its peptide-based new drug pipelines including ‘NP-201,’ drug delivery platform technologies, active pharmaceutical ingredient CDMO (Contract Development and Manufacturing Organization) business, and bio-materials.
During BIO USA, Naivek held numerous business meetings with pharmaceutical companies, among which ‘NP-201’ attracted the most attention. The company explained that this was because NP-201 had successfully completed a global Phase 1 clinical trial in Australia and is preparing for Phase 1b/2a clinical trials in the United States.
NP-201 is a new drug candidate aimed at fundamental treatment such as regeneration of damaged cells, not merely an anti-inflammatory therapeutic. Initially developed as the first pulmonary fibrosis (PF) treatment, its indication was expanded to inflammatory bowel disease (IBD) while preparing for Phase 2 clinical trials, and recently research has also been extended to pulmonary arterial hypertension (PAH).
A Naivek official stated, “Although there were many discussions on each business and pipeline at the site, big pharma showed the greatest interest in NP-201,” adding, “There were many requests for detailed explanations and materials on NP-201’s indications, so we conducted multiple focused presentations and separately provided summaries containing scientific data including safety information.”
He continued, “Even after returning to Korea, we are continuing follow-up discussions through additional online responses and Zoom meetings,” and added, “We believe the significant interest stems from the fact that NP-201 aims to enter Phase 2 clinical trials in the US this year and is based on regeneration promotion rather than antagonism.”
Active discussions were also held with global pharmaceutical companies on technology partnerships in the fields of anticancer and brain disease therapeutics. Earlier in April, Naivek participated in the ‘American Association for Cancer Research (AACR),’ one of the world’s top three cancer conferences, where it disclosed research results and data on its self-developed K-RAS targeted degradation anticancer drug. Follow-up meetings related to this were held at BIO USA.
According to industry sources, with the FDA’s final approval pending for Eli Lilly’s Alzheimer’s disease treatment ‘Donanemab,’ drawing attention to the related field, Naivek also held numerous meetings regarding its proprietary blood-brain barrier (BBB) permeable delivery system. It discussed partnerships with 15 companies in this field, including existing partners and pharmaceutical companies that recently expanded indications of related therapeutics to neuropathy.
A company representative explained, “In addition, in the drug delivery platform field, we succeeded in securing new partners including two US pharmaceutical companies with whom we are already collaborating,” adding, “There is a high possibility of conducting new projects based on nano-complexes that combine our proprietary drug delivery platform ‘NIPEP-TPP’ with ‘antisense oligonucleotides (ASO)’ or ‘small interfering RNA (siRNA)’ with the said company.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
